Researchers Determine Best Metrics for Predicting Survival in Ewing Sarcoma

Share this content:
FDG-PET testing that shows early progression of patients with Ewing sarcoma is linked to reduced overall survival.
FDG-PET testing that shows early progression of patients with Ewing sarcoma is linked to reduced overall survival.

Fluorodeoxyglucose positron emission tomography (FDG-PET) testing that shows early progression of patients with Ewing sarcoma is linked to reduced overall survival, according to an article published in the Journal of Clinical Oncology.1

Researchers analyzed data from a clinical trial evaluating the efficacy of a novel antibody; various evaluative measures for survival were analyzed to compare effectiveness.

Volume analysis and signals of early progression at day 9 predicted a worse overall survival rate. PET tests were more accurate predictors than anatomic imaging; volume analysis, however, was the best method of identifying which patients responded.

RELATED: Sentinel Lymph Node Biopsy Recommended for Patients With Sarcoma

The authors conclude that although analyses of volume require validation, both volume analysis and activity noted with FDG-PET were the most likely to accurately predict the survival benefit of the tested antibody.

Reference

  1. Koshkin VS, Bolejack V, Schwartz LH, et al. Assessment of imaging modalities and response metrics in Ewing sarcoma: correlation with survival. J Clin Oncol. 2016 Aug 29. doi: 10.1200/JCO.2016.68.1858 [Epub ahead of print]

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs